Episode 3 of our monthly GU Cast Journal Club and today we focus on one classic paper in Urology, and one from recent times - the ERSPC randomised trial of screening in prostate cancer, and the NIAGARA trial evaluating peri-operative immunotherapy in muscle-invasive bladder cancer. We are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy. Watch out for Declan getting all misty-eyed recalling when the ERSPC was published back in 2009 (the rest of the team are too young to remember this)!

Another of our deep-in-the-weeds theranostic webinars in conjunction with our friends at ProsTiC, and the Prostate Cancer Foundation. This one focussed on Terbium-161, a very exciting new option in metastatic prostate cancer. Your hosts are Dr Renu Eapen and Professor Michael Hofman, with Dr Howard Soule and Dr Andrea Miyahira from the Prostate Cancer Foundation. Special guests include Dr James Buteau (Peter Mac, Melbourne, Australia), Dr Alin Chirindel (Universitätsspital Basel), Prof Dr Samer Ezziddin (Saarland University Hospital, Germany) and Prof. Cristina Müller (Paul Scherrer Institute, Switzerland)

Hot off the press in the Presidential Plenary at #ESMO25, we chat with Dr Scott Tagawa (Weill-Cornell, USA) about the positive data he just presented from the PSMAddition trial. This is an eagerly awaited phase III randmosied trial of patients with mHSPC, to see if the addition of six cycles of Lu-PSMA-617 to a control arm of ADT and an ARPI, could improve rPFS and other endpoints. We are also joined in the studio by Prof Michael Hofman (Peter MacCallum Cancer Centre, AUS), co-PI of the UpFront PSMA trial which also explored a similar concept, plus some comments from our other colleague, prof Arun Azad, who was the Discussant in the Presidential at ESMO25.

Never heard of Common Sense Oncology?? Well if you enjoy this podcast then we think you will might find the Common Sense Oncology (CSO) movement to be very interesting indeed! Declan Murphy caught up recently with Dr Bishal Gyawali, Medical Oncologist at Queen's University, Kingston, Ontario, to talk about CSO which he co-founded in 2023. They are on a mission to ensure that cancer care and innovation, should focus on results that are meaningful to patients (eg survival, quality of life, equity), rather than just regulatory approval, commercial success, or statistical endpoints. "Outcomes that matter", is their battle cry.

The Urological Association of Asia (UAA) Annual Meeting is always a great cultural event with a focus on the local community. And Taipei certainly put on a great show! Lots of fantastic entertainment and great local cuisine, plus of course a great scientific program, with a focus on AI, single port robotic surgery, novel robot systems, and lots more across the breadth of Urology. Join hosts Renu Eapen and Declan Murphy, who bring you a great flavour of UAA in Taipei, speaking to many local and international guests.

They started off by introducing themselves as The Three Horsemen of the Apocalypse - what could possibly go wrong!! Declan couldn't resist the opportunity to invite three very eminent radiation oncologists into the studio when they all happened to be in Melbourne, even if he was particularly outnumbered while Renu was away! Vedang Murthy (Tata Memorial, India), Andrew Loblaw (Sunnybrook Hospital, Canada), and Sarat Chander (Peter Mac, Melbourne) are all highly specialised in prostate radiation, so Declan invited them into the GU Cast studio to pick their brains on three big areas in prostate radiation.

We never need an excuse to visit Sydney, and for sure when one of our favourite meetings of the year is in the Harbourside City then count us in! The Annual Meeting of ANZUP is something we try and get to every year and have really enjoyed bringing you highlights. This year we catch up with some international faculty including Roger Li (Moffitt Cancer Centre, USA), ANZUP Prostate Cancer Committee bosses Lisa Horvath (Chris O'Brien Lifehouse) and Jarad Martin (Genesis Care), Dickon Hayne (Fiona Stanley Hospital) regarding his NMICB RCT, and Bernie Reilly (Prostate Cancer Foundation of Australia) about some fantastic resources for prostate cancer patients.

Episode 2 of our monthly GU Cast Journal Club and today we focus on two key papers from recent times - the TRANSLATE trial of transperineal vs transrectal biopsy, and Keynote-564 on the role of adjuvant pembrolizomab following nephrectomy. After great feedback from last month's launch episode, we are delighted to welcome back our GU Cast Journal Club Editors, Dr Carlos Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER), along with main GU Cast Hosts, Renu Eapen and Declan Murphy

We poke around under the hood of a brand new Cyberknife facility here in Melbourne, the first on the East coast of Australia, and find out what it's all about. What is it for, who might benefit, and being surgeons we have to ask, why do they call it a "knife"?! Is it just to make it sound a bit like surgery - stay tuned to find out!

Big news today with the publication in JAMA of the eagerly anticipated PRIME study, a prospective multicentre trial comparing biparametric (bp) with multiparametric (mp) MRI in men suspected of having prostate cancer. Of course, mpMRI includes contrast enhanced sequences following injection of gadolinium, adding time, cost, plus the burden of gadolinium to bpMRI, and there have been suggestions that bpMRI may be just as effective as mpMRI for detecting clinically significant prostate cancer.

A quick pod to promote the totally free WRSE12 Live Robotic Surgery Event coming up later this month! A 12 hour festival of incredible robotic surgery performed by top surgeons from around the world, with a special focus on real time digital pathology using the very promising Histolog technology that we recently featured on GU Cast. Live surgeries include upper and lower tract, with an array of robotic technology including the da Vinci Single Port robot.

ne of our most popular podcasts ever was the one called "Gleason 6 prostate cancer | Why we should rename it (and why we can't)!", posted in December 2022, and featuring Urologists Scott Eggener (Chicago) and Matt Cooperberg), plus Pathologist Eva Comperat (Paris/Vienna). In fact, we still get so many hits on this and active comments on our YouTube site that we thought we better re-visit it!!! Is Gleason 6/Grade Group 1 really cancer at all?? Can't we just re-name it and declare it not-a-cancer??!

ere it is, the first of our new series called GU Cast Journal Club! A dedicated GU Cast Journal Club has been suggested by many of our listeners and viewers over the years, and we are really pleased to kick off today with the first monthly episode. And we are particularly pleased to introduce our GU Cast Journal Club Editors, Dr Carlso Delgado (Melbourne, AUS), and Dr Elena Berg (Munich, GER).

Now this a topic we are ashamed to say we have barely covered in five plus years of GU Cast! A well overdue deep dive into the management of penile cancer, the rarest of all GU cancers, and fair to say the one that gets the least attention, not just from us, but from those who found research/education/novel therapies etc. We are joined in studio by two world-leading experts in penile cancer, Professors Asif Muneer (University College London), and Nathan Lawrentschuk (Royal Melbourne Hospital & Peter MacCallum Cancer Centre), to cover all the key topics in penile cancer. Everything from peculiarities in incidence, gender-neutral HPV vaccination, right up to organ-preserving surgery and optimal lymph node dissection techniques. Plus a fascinating peak into an AI project of Nathan's focussing on penile cancer diagnosis.

Refresh your knowledge of testis cancer with this punchy pod with testis cancer gurus, Prof Christian Kollmannsberger (Vancouver Cancer Centre, Vancouver), and Prof Ben Tran (Peter MacCallum Cancer Centre, Melbourne). We pick their brains on three topical areas in testis cancer; 1. Adjuvant chemo - balancing early gains vs late effects. How can we figure out who benefits? 2. Primary RPLND - does robotic surgery change the value proposition of surgery vs chemotherapy? 3. The outstanding mi371 tumour marker - a bluffer's guide

Renu was in Taipei recently and caught up with Prof Jacob Pang, Urologist and President of the Urological Association of Asia Annual meeting which takes place in Taipei from 14-17 August 2025. Find out why you should attend in this quick pod!

What do Lions Rugby and Cardio-oncology have in common?? Well tune in to this episode of GU Cast to find out! The incidence of cardiovascular disease is high in our patients with advanced prostate cancer (more than maybe we appreciate), plus fundamental treatments such as androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPIs) further increase the risk of cardiovascular events. And now there is a multidisciplinary field called cardio-oncology which is set to address all of this. How do we (simply) assess cardiovascular risk? Who needs to be optimised? What do we need to know about LHRH analogues vs anatagonists? What about ARPIs and drug-drug interactions with statins and blood thinners? Superb studio guest today to discuss all of this, and our first ever Cardiologist! Dr Alex Lyon (Royal Brompton Hospital, London) is a world renowned expert in cardio-oncology and joined us to run through a bit of a dummy’s guide to prostate cardio-oncology. With your usual hosts, Renu Eapen and Declan Murphy.

Another in our series of Themed Podcasts focussing on GU Oncology in China. We are joined by our China Editor, Dr Yao Zhu (Fudan University, Shanghai), and Prof Xuedong Wei (Soochow University, Jiangsu). to find out what the current treatment landscape is for mHSPC in China. Is it ADT/ARPI doublets for all?? Anyone still give chemo? Who gets a PSMA PET/CT? And what is the current status and role for radioligand therapy at progression? Plus, when are we taking GU Cast to China again?! All this and more!

Those two gigantic PSMA review papers in European Urology - Perera et al 2016 and Perera et al 2020 - have been cited more than 2000 times and have been the definitive reference for anyone writing about PSMA PET/CT in the past ten years. And they have just been updated in two new papers just published in European Urology! Previous first author (Marlon) Perera, has moved to senior author, while Elio Mazzone has led both papers as first author, co-ordinating a massive effort between research teams in Melbourne and Milano. One paper is focused on diagnosis and staging, and the other on assessment of recurrence.

A beachside interview with Michael Hofman to hear all the PSMA theranostic highlights at ASCO this year! Yes we left our suburban studio in Melbourne and wandered down to St Kilda beach to track down Michael for a beer and a chat. Even in mid-Winter we enjoyed sitting out in a beachside shack at the Beachcomber Cafe and Beach Bar.